Tekla Healthcare Investors (HQH)
22.05
+0.02 (+0.09%)
USD |
Dec 02, 20:00
Price Chart
Key Stats
Customize
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 1.12% | -10.70% | 1.081B | 149972.0 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.00% | 47.65% | -- | Upgrade |
Basic Info
| Investment Strategy | |
| To achieve long-term capital appreciation by investing at least 80% of its assets in securities of health services and medical technology companies. The Trust may invest up to 20% of its net assets in non-US securities and up to 40% in venture capital or other securities subject to legal or contractual restrictions as to resale. |
| General | |
| Security Type | Closed-End Fund |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Hambrecht & Quist |
| Prospectus Benchmark Index | |
| NASDAQ Biotechnology TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Daniel Omstead | 19.10 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
--
-4.011B
Category Low
2.782B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
Date Unavailable
Performance Versus Category
As of December 01, 2020. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
Edit comparables
As of December 01, 2020.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | 7.25% | 226.70 | -1.56% |
| Amgen Inc | 6.85% | 226.56 | 0.66% |
| Regeneron Pharmaceuticals Inc | 6.17% | 505.13 | -1.74% |
| Gilead Sciences Inc | 6.05% | 61.13 | 0.02% |
| Illumina Inc | 4.06% | 340.82 | 1.94% |
| Biogen Inc | 3.08% | 246.92 | 1.55% |
| Seattle Genetics Inc | 2.46% | 177.04 | -0.21% |
| Alexion Pharmaceuticals Inc | 2.17% | 122.75 | 0.49% |
| Moderna Inc | 1.93% | 143.00 | 1.41% |
| Biomarin Pharmaceutical Inc | 1.82% | 79.86 | 0.45% |
News
Headline
Wire
Time (ET)
Basic Info
| Investment Strategy | |
| To achieve long-term capital appreciation by investing at least 80% of its assets in securities of health services and medical technology companies. The Trust may invest up to 20% of its net assets in non-US securities and up to 40% in venture capital or other securities subject to legal or contractual restrictions as to resale. |
| General | |
| Security Type | Closed-End Fund |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Hambrecht & Quist |
| Prospectus Benchmark Index | |
| NASDAQ Biotechnology TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Daniel Omstead | 19.10 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (12-2-20) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 23.23 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of June 30, 2020
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 4/23/1987 |
| Last Annual Report Date | 9/30/2019 |
| Last Prospectus Date | 2/7/1997 |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan |
|
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)